Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

A Long-term Observational Study Evaluating Sarepta Therapeutics, Inc's Exon-Skipping Therapies in Patients with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice

Sarepta Registry 4658-403

Condition: Neurology
Phase: IV

What is the goal of the study?

An observational study that is designed to collect available data on DMD patients receiving an FDA approved exon skipping drug in routine clinical practice. Data will be collected from the medical record after routine visits for at least 5 years.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Seth Perlman
Study Team Member: Macarena Racciatti, Maria.Racciatti@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.